Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target

Stock Track11-07

Iovance Biotherapeutics, Inc. (IOVA) saw its stock plummet 6.32% in pre-market trading, following a significant price target cut by Chardan Capital Markets. The sharp decline comes as investors react to the lowered expectations for the biotechnology company's stock performance.

Chardan reduced its price target for Iovance Biotherapeutics from $20 to $17, representing a 15% decrease. Despite the cut, Chardan maintained its "Buy" rating on the stock. This move contrasts with the broader analyst consensus, which, according to FactSet, rates IOVA as "overweight" with a mean price target of $7.75. The disparity between Chardan's new target and the average suggests a wide range of opinions among analysts regarding the company's prospects.

The market's strong negative reaction to the price target cut highlights investor sensitivity to changing analyst perspectives, especially in the volatile biotechnology sector. While Chardan's maintained "Buy" rating indicates some optimism, the significant pre-market drop suggests that investors are more focused on the near-term implications of the lowered price target. As the regular trading session begins, market participants will be closely watching IOVA's performance to gauge whether this pre-market plunge is a temporary setback or the start of a more prolonged downturn.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165132156?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 23:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165132156","market":"sg","top_or_hot":-1,"title":"Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target","media":"Stock Track","content":"<p>Iovance Biotherapeutics, Inc. (IOVA) saw its stock plummet 6.32% in pre-market trading, following a significant price target cut by Chardan Capital Markets. The sharp decline comes as investors react to the lowered expectations for the biotechnology company's stock performance.</p>\n\n<p>Chardan reduced its price target for Iovance Biotherapeutics from $20 to $17, representing a 15% decrease. Despite the cut, Chardan maintained its \"Buy\" rating on the stock. This move contrasts with the broader analyst consensus, which, according to FactSet, rates IOVA as \"overweight\" with a mean price target of $7.75. The disparity between Chardan's new target and the average suggests a wide range of opinions among analysts regarding the company's prospects.</p>\n\n<p>The market's strong negative reaction to the price target cut highlights investor sensitivity to changing analyst perspectives, especially in the volatile biotechnology sector. While Chardan's maintained \"Buy\" rating indicates some optimism, the significant pre-market drop suggests that investors are more focused on the near-term implications of the lowered price target. As the regular trading session begins, market participants will be closely watching IOVA's performance to gauge whether this pre-market plunge is a temporary setback or the start of a more prolonged downturn.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 23:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Iovance Biotherapeutics, Inc. (IOVA) saw its stock plummet 6.32% in pre-market trading, following a significant price target cut by Chardan Capital Markets. The sharp decline comes as investors react to the lowered expectations for the biotechnology company's stock performance.</p>\n\n<p>Chardan reduced its price target for Iovance Biotherapeutics from $20 to $17, representing a 15% decrease. Despite the cut, Chardan maintained its \"Buy\" rating on the stock. This move contrasts with the broader analyst consensus, which, according to FactSet, rates IOVA as \"overweight\" with a mean price target of $7.75. The disparity between Chardan's new target and the average suggests a wide range of opinions among analysts regarding the company's prospects.</p>\n\n<p>The market's strong negative reaction to the price target cut highlights investor sensitivity to changing analyst perspectives, especially in the volatile biotechnology sector. While Chardan's maintained \"Buy\" rating indicates some optimism, the significant pre-market drop suggests that investors are more focused on the near-term implications of the lowered price target. As the regular trading session begins, market participants will be closely watching IOVA's performance to gauge whether this pre-market plunge is a temporary setback or the start of a more prolonged downturn.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1165132156","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165132156","pubTimestamp":1762527833,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Iovance Biotherapeutics, Inc. (IOVA) saw its stock plummet 6.32% in pre-market trading, following a significant price target cut by Chardan Capital Markets. The sharp decline comes as investors react...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"股票追踪|Chardan下调目标价，Iovance Biotherapeutics暴跌6.32%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Iovance Biotherapeutics, Inc. (IOVA) saw its stock plummet 6.32% in pre-market trading, following a significant price target cut by Chardan Capital Markets. The sharp decline comes as investors react to the lowered expectations for the biotechnology company's stock performance.\nChardan reduced its price target for Iovance Biotherapeutics from $20 to $17, representing a 15% decrease. Despite the cut, Chardan maintained its \"Buy\" rating on the stock. This move contrasts with the broader analyst consensus, which, according to FactSet, rates IOVA as \"overweight\" with a mean price target of $7.75. The disparity between Chardan's new target and the average suggests a wide range of opinions among analysts regarding the company's prospects.\nThe market's strong negative reaction to the price target cut highlights investor sensitivity to changing analyst perspectives, especially in the volatile biotechnology sector. While Chardan's maintained \"Buy\" rating indicates some optimism, the significant pre-market drop suggests that investors are more focused on the near-term implications of the lowered price target. As the regular trading session begins, market participants will be closely watching IOVA's performance to gauge whether this pre-market plunge is a temporary setback or the start of a more prolonged downturn.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165132156","isCrawlerRequest":true}